title: Patient perception and use of an insulin injector/glucose monitor combined device.
abstract: This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor.
  
  
  
  In a randomized, multicenter, 2-period crossover study, 15 patients with type 1 diabetes were randomized to use either a combined injector/monitor device or syringes, a vial, and a separate glucose monitor, then switched to the alternate treatment. Efficacy, safety, preference, satisfaction, and actual use (via meter download) of the 2 systems were compared.
  
  
  
  Most of the patients preferred using the combination device to syringes and a separate meter. Results from the Handling of Delivery Systems questionnaire given at the end of the study indicated that 49% of patients felt they tested their blood glucose more often with the combination device than with a separate meter. A higher frequency of daily monitoring was reported with the combination device in patients overall (approximately 1 more reading per week). However, a large subset of patients (32%) showed substantial increases in their frequency of daily glucose monitoring (an average of 1 additional reading per day).
  
  
  
  Use of the combination device was associated with significant improvements in patient treatment satisfaction.
authors.affiliation: Atlanta Diabetes Associates, Georgia
authors.forename: Bruce
authors.initials: B
authors.lastname: Bode
authors.affiliation: Lawrenceville, New Jersey
authors.forename: John
authors.initials: J
authors.lastname: Shelmet
authors.affiliation: Melbourne Internal Medicine Associates, Melbourne, Florida
authors.forename: Brent
authors.initials: B
authors.lastname: Gooch
authors.affiliation: Comprehensive Clinical Research, Berlin, New Jersey
authors.forename: David R
authors.initials: DR
authors.lastname: Hassman
authors.affiliation: Novo Nordisk Pharmaceuticals, Princeton, New Jersey
authors.forename: John
authors.initials: J
authors.lastname: Liang
authors.affiliation: Novo Nordisk A/S, Sorgenfri, Denmark
authors.forename: Jorgen K
authors.initials: JK
authors.lastname: Smedegaard
authors.affiliation: Novo Nordisk A/S, Sorgenfri, Denmark
authors.forename: Soren
authors.initials: S
authors.lastname: Skovlund
authors.affiliation: Novo Nordisk A/S, Sorgenfri, Denmark
authors.forename: Birgitte
authors.initials: B
authors.lastname: Berg
authors.affiliation: Novo Nordisk Pharmaceuticals, Princeton, New Jersey
authors.forename: William
authors.initials: W
authors.lastname: Lyness
authors.affiliation: Division of Endocrinology, Metabolism, and Nutrition, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Schneider
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001294:Attitude to Health; D015190:Blood Glucose Self-Monitoring / Q000009:adverse effects / Q000295:instrumentation* / Q000523:psychology; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology; D004867:Equipment Design; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007279:Injections, Subcutaneous / Q000009:adverse effects / Q000295:instrumentation* / Q000523:psychology; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D012449:Safety; D012646:Self Administration / Q000295:instrumentation / Q000523:psychology; D011795:Surveys and Questionnaires; D014481:United States
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin